<DOC>
	<DOCNO>NCT00555997</DOCNO>
	<brief_summary>This study effectiveness , tolerability safety oral ziprasidone monotherapy patient major depressive disorder ( MDD ) . Outpatients suffer MDD treat either ziprasidone placebo 12 week . Hypothesis : There statistically significant difference magnitude response , measure decrease baseline 17-item Hamilton Depression Rating Scale ( HAM-D-17 ) score , two treatment group ; reduction HAM-D-17 score great ziprasidone monotherapy group placebo group .</brief_summary>
	<brief_title>A 12-Week , Placebo Controlled Trial Ziprasidone Monotherapy Major Depressive Disorder</brief_title>
	<detailed_description>Exploratory hypothesis 1 : There statistically significant difference percentage responder two treatment group ; response rate significantly high ziprasidone monotherapy compare placebo group . Exploratory hypothesis 2 : The change 6-VAS-D score trial highly correlated change HAM-D-17 QIDS-SR trial .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>1 . Age 1865 . 2 . Written informed consent . 3 . MDD , current accord fourth version Diagnostic Statistical Manual Mental Disorders ( DSMIV ) diagnose Mini International Neuropsychiatric Interview ( MINI ; Sheehan et al , 1998 ) . 4 . Quick Inventory Depressive Symptomatology SelfRated ( QIDSSR Trivedi et al , 2004 ) score least 10 screen baseline visit . 1 . Pregnant woman . 2 . Women child bear potential use medically accept mean contraception ( include oral contraceptive implant , condom , diaphragm , spermicide , intrauterine device , tubal ligation , partner vasectomy ) . 3 . Treatment antidepressant 2 week prior screen visit . If interested discontinue current medication , potential participant must discuss possibility prescribe physician . Study doctor implement form treatment washout . 4 . Patients longer meet DSMIV criterion MDD baseline visit , patient demonstrate 25 % great reduction QIDSSR score , screen baseline . 5 . Serious suicide homicide risk , assess evaluate clinician score 4 third item HAMD . 6 . Unstable medical illness include cardiovascular , hepatic , renal , respiratory , endocrine , neurological , hematological disease . 7 . Patients meet criterion alcohol substance dependence , active within last month . 8 . Any bipolar disorder ( current past ) . 9 . Any psychotic disorder ( current past ) . 10 . Psychotic feature current episode history psychotic feature . 11 . History seizure disorder . 12 . Clinical laboratory evidence untreated hypothyroidism . 13 . Patients require excluded medication ( see table 1 detail ) . 14 . Prior course ziprasidone , intolerance ziprasidone dose . 15 . Any investigational psychotropic drug within last 3 month . 16 . Patients significant cardiac conduction problem screen electrocardiogram atrial fibrillation , atrial flutter , atrioventricular block , prolong abnormal QTc interval ( i.e . QTc &gt; 450msec ) , prolong QRS interval . 17 . Patients suffer myocardial infarction within past 12 month , uncompensated heart failure , history QTc prolongation . 18 . Patients abnormal serum potassium magnesium level upon screen . 19 . Patients currently take drug prolong QTc include dofetilide , sotalol , quinidine , class Ia antiarrhythmic , class III antiarrhythmic , mesoridazine , thioridazine , chlorpromazine , droperidol , pimozide , sparfloxacin , gatifloxacin , moxifloxacin , halofantrine , mefloquine , pentamidine , arsenic trioxide , levomethadyl acetate , dolasetron methylate , probucol tacrolimus . 20 . Patients fail experience significant clinical improvement follow 3 antidepressant trial adequate duration ( least 6 week ) dose ( minimal effective dos define : fluoxetine , paroxetine , citalopram 20mg ; sertraline , fluvoxamine 50mg , escitalopram 10mg , paroxetine CR 25mg , venlafaxine 75mg , duloxetine 60mg , bupropion 150mg , 15mg mirtazapine , trazodone nefazodone 300mg ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Major Depression</keyword>
	<keyword>Depression</keyword>
	<keyword>Geodon</keyword>
	<keyword>Ziprasidone</keyword>
</DOC>